 ACH
806 (HCV Protease Inhibitor)
In
Vitro Studies Suggest Promising Outcomes with New HCV Protease Inhibitor ACH
806 in Combination with Interferon, Telaprevir, or NM 107
- 5/05/07
Albumin
Interfern
Albuferon
Dose in Ongoing Trials is Lowered Due to Safety Concerns - 1/25/08
Albumin
Interferon May Be as Effective as Pegylated Interferon with Less Frequent
Dosing -
5/05/07
Boceprevir
(aka SCH 503034)
Polymerase
Inhibitor NM107 and Protease Inhibitor Boceprevir
Show Enhanced Anti-HCV Activity in Combination -
12/07/07
Enhanced
Clinical Effects and Favorable Resistance Profile with Combination of Boceprevir
Plus HCV-796
- 5/20/07
Schering’s
Experimental Oral HCV Protease Inhibitor Boceprevir Appears Safe
in Patients with Varying Degrees of Liver Impairment
- 5/05/07
Mutations
That Confer Resistance to HCV Protease Inhibitors 5/05/07
Combining
Experimental HCV Inhibitors Boceprevir and NM 107 Enhances Anti-HCV Activity
and Suppresses Emergence of Resistance
- 5/05/07
Mutations
That Confer Resistance to HCV Protease Inhibitors 5/01/07
In
Vitro Studies Suggest Promising Outcomes with New HCV Protease Inhibitor ACH 806
in Combination with Interferon, Telaprevir, or NM 107 4/05/07
Update
on Clinical Development Program for HCV Protease Inhibitor SCH 503034
- 4/28/06
THE
HCV NS3 PROTEASE INHIBITOR SCH 503034 IN COMBINATION WITH PEG-IFN-ALPHA-2B
IN THE TREATMENT OF HCV-1 PEG-IFN-ALPHA-2B NON-RESPONDERS: ANTIVIRAL ACTIVITY
AND HCV VARIANT ANALYSIS
- 4/28/06
Open
Clinical Trial of New PI SCH 503034 Plus PegIntron in HCV Patients Nonresponsive
to Prior Treatment with Peginterferon Plus Ribavirin - 2/17/06
Celgosivir
Adding
Celgosivir to Standard Hepatitis C Therapy Increases the Likelihood of
Early Response Rate in Prior Non-responders
- 5/05/07
Celgosivir:
Well-Tolerated, but Minimal Anti-HCV Activity as Monotherapy
- 6/06/06
GS
9132 and
GS 9190
Experimental
HCV Polymerase Inhibitor GS
9190 Shows
Promising Antiviral Activity but Possible Cardiac Side Effects in Phase 1 Study
- 12/11/07
Despite
Promising Early Data, Companies Discontinue Experimental HCV Protease Inhibitor
GS 9132
-
2/13/07
Gilead
and Achillion Announce Start of Phase 1 Clinical Trial of GS 9132, an HCV
Protease Inhibitor for the Treatment of Hepatitis C
- 8/24/05
HCV-796
(HCV Polymerase Inhibitor) Novel
HCV Polymerase Inhibitor VCH-759 Monotherapy
Demonstrates Promising Antiviral Activity -
12/07/07
Experimental
Polymerase Inhibitor
HCV-796 is
Safe and Effective in Combination with PegIntron or Pegasys - 12/07/07
HCV-796
Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than
Either Agent Used Alone
- 5/20/07
Enhanced
Clinical Effects and Favorable Resistance Profile with Combination of Boceprevir
Plus HCV-796
- 5/20/07
HCV-796
Shows Antiviral Activity in Combination with Pegylated Interferon - 5/05/07
Experimental
Agent HCV-796 Shows Activity in Preclinical Studies
- 10/03/06
HCV
Polymerase Inhibitor VCH-759 Novel
HCV
Polymerase Inhibitor VCH-759 Monotherapy
Demonstrates Promising Antiviral Activity -
12/07/07
ITMN
191 (HCV Polymerase Inhibitor)
InterMune
Presents Top-line Results from Phase 1b Trial of HCV Protease Inhibitor ITMN-191
Monotherap -
4/04/08
InterMune
Announces Progress on HCV
Protease Inhibitor ITMN-191 - 1/11/08
Preclinical
Study Shows ITMN-191 Plus Pegasys is Active against HCV In Vitro
11/10/06
Roche
and InterMune to Collaborate on HCV Protease Inhibitor ITMN-191
10/24/06
Preclinical Data on New
HCV Protease Inhibitor ITMN 191- 6/02/06
MK-06080
(HCV Nucleoside Inhibitor)
Experimental
Nucleoside Inhibitor MK-0608 Suppresses HCV Replication in Chimpanzees
9/29/06
R-1626
and R7128 (HCV Polymerase Inhibitor)
Pharmasset
Announces Promising 4-Week Data on Combination Therapy with
HCV Polymerase Inhibitor R7128 -
1/11/08
HCV
Polymerase Inhibitor R7128 Demonstrates
Antiviral Activity in Prior Non-responders -
12/14/07
Pharmasset
Completes Enrollment for Phase 1 Study of Experimental Nucleoside Polymerase Inhibitor
R7128 for Treatment of Chronic Hepatitis C
- 8/07/07
Pharmasset
and Roche Initiate New Toxicology Studies of
HCV Polymerase Inhibitor R7128 - 7/13/07
Roche
Polymerase Inhibitor R1626 Demonstrates Antiviral Activity and Good Safety
in Phase I Study
11/10/06
HCV
Polymerase Inhibitor R-1626 Advances to Phase II Study 10/17/06
New
Oral Polymerase Inhibitor Shows Promising Results in Chronic Hepatitis C Patients
5/02/06
Valopicitabine
(HCV Polymerase Inhibitor)
Two
Studies Yield Mixed Results for HCV Polymerase Inhibitor Valopicitabine
- 5/05/07
Valopicitabine
Dosed in Combination with Pegylated Interferon Alfa-2a (Pegasys) Leads to Rapid
Virologic Response in 93 percent of Genotype 1 Hepatitis C Patients
- 1/05/06
Lower
Dose of Valopicitabine plus Pegylated Interferon Shows Antiviral Activity
with Fewer Side Effects
- 11/15/06
Valopicitabine
plus Peginterferon Alfa-2a (Pegasys) Is More Effective in Nonresponders Compared
to Peginterferon alfa-2a/Ribavirin Combination Treatment -
5/12/06
Randomized
Trial of Valopicitabine (NM 283), Alone or with Peginterferon, vs Retreatment
with Peginterferon Plus Ribavirin in Nonresponders to Peginterferon Alfa
- 11/14/05
No
Effect of Pegylated Interferon Alfa-2b (PegIntron) on the Pharmacokinetics of
Valopicitabine (NM 283) in Chronic HCV Patients
- 11/14/05
Encouraging
Interim Results of Phase II Study of Valopicitabine (NM-283) in Combination
with Peginterferon Alfa in Patients with HCV Genotype 1 -
1/05/05
Viramidine
Virological
Response and Safety Outcomes in Chronic Hepatitis C Patients Treated with Pegylated
Interferon plus Taribavirin (Viramidine)
- 8/10/07
Hepatitis
C Drug Viramidine Fails Pivotal Phase III Trial, Again
9/15/06
Valeant Announces
Results of Phase 3 VISER 1 Trial Results of Viramidine versus Ribavirin
- 3/24/06
Telaprevir
(aka VX-950)
monotherapy / combination
Vertex
to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir (VX-950)
- 2/01/08
Telaprevir
plus Pegylated Interferon
Is Effective against Both Wild-type and Drug-resistant HCV Strains
- 8/17/07
Mutations
That Confer Resistance to HCV Protease Inhibitors 5/01/07
Telaprevir-based
Therapy for HCV May Shorten Treatment Duration from 48 to 24 Weeks for Some
Genotype 1 Patients -
4/17/07
In
Vitro Studies Suggest Promising Outcomes with New HCV Protease Inhibitor ACH 806
in Combination with Interferon, Telaprevir, or NM 107 4/05/07
Telaprevir
Demonstrates Safety and Anti-HCV Activity in 12-week Interim Analysis 1/05/07
Telaprevir
Resistance Mutations Observed in Laboratory Studies 12/05/06
Updated
Results from Patients Receiving Standard HCV Therapy Following Telaprevir 12/01/06
Telaprevir
plus Pegylated Interferon Suppresses Wild-type and Resistant HCV Over 14 Days
11/03/06
Rapid
Decline of HCV RNA in Patients Treated with VX-950 10/02/06
12
of 12 Patients Receiving Experimental HCV Protease Inhibitor VX 950 in Combination
with Pegasys Plus Ribavirin for 28 Days Experience Undetectable HCV RNA Levels- 5/23/06
Small
Study Shows HCV RNA Levels Undetectable in 12 of 12 HCV Genotype 1 Patients after
4 Weeks of Treatment with Experimental HCV Drug VX 950 Plus Pegasys
and Ribavirin -
2/10/06
Experimental
Oral Protease Inhibitor VX-950 from Vertex Produces Rapid and Dramatic
Reduction in HCV RNA in Combination with Pegylated Interferon Alfa-2a
(Pegasys) - 1/10/06 | 
FDA-approved
Treatments
